Spike New Drug Approved for Registration


Release time:

2019-04-23

 4Month16On the same day, Jianfeng Pharmaceutical Company received the Drug Registration Approval of Olopatadine Hydrochloride Eye Drops approved and issued by the State Drug Administration (approval number:2019S00296)。

Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis, is a mast cell stabilizer and relatively selective histamine H1-receptor antagonists, which inhibit both in vivo and in vitroIAnaphylaxis. At present, the product has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017Year Edition), classified as Class B. AccordingIMSThe relevant data of the database,2018Global sales of olopatadine hydrochloride eye drops in3.7Billion US dollars, China sales of about1023.2million dollars.

Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business.